Neurocrine Biosciences, Inc. (NASDAQ: NBIX) boasted a stock that gained ground Monday on new developments over the next few days.
The company today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed Care Pharmacy (AMCP) 2022 annual meeting in Chicago on March 29–April 1. The three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic CAH.
According to Eiry Roberts, Chief Medical Officer at the Company, "There are currently no non-steroidal U.S. FDA-approved treatments for classic CAH, which means management of the condition can be challenging for patients and caregivers alike.
"The data we are presenting at AMCP 2022 reinforce the challenges of managing classic CAH among patients living with this condition, with a treatment paradigm that has remained unchanged for more than 60 years. These studies underscore our commitment to improving the scientific and medical community's understanding of classic CAH and the limitations of the current standard of care, and are instrumental in guiding our efforts to advance new treatment options."
Classic CAH due to 21-hydroxylase deficiency (21-OHD) is a rare autosomal recessive condition characterized by cortisol deficiency and elevated adrenocorticotropic hormone (ACTH) secretion, resulting in excess androgen production. The current standard of care is glucocorticoid (GC) therapy to replace endogenous cortisol deficiency; however, supraphysiologic GC doses are often needed to reduce elevated ACTH secretion and excess androgen production.
NBIX shares hiked 48 cents to $49.20.
